Compare JD.Com Inc (JD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Zimmer Biomet Holdings Inc — how do they compare? JD.Com Inc trades at $27.18 (market cap $36.62B), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: JD.Com Inc is far larger — about 2.2× Zimmer Biomet Holdings Inc's market cap, and JD.Com Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| JD | ZBH | |
|---|---|---|
Market Cap | $36.62B | $16.95B |
Volume | 6,571,477 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $103.98 |
52-Week Low | $25.19 | $79.58 |
Typical Hold Time | 85 Days | 89 Days |
Enterprise Value | $19.26B | $24.02B |
Dividend Yield | 3.72% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com stock trades at $27.03, up 2.0% today, with a bullish technical signal and strong analyst consensus. The company reported revenue of $1.31 trillion in 2025, though net income declined to $19.63 billion. Recent news highlights potential EU approval for its $2.5 billion Ceconomy acquisition, a key strategic move.
The outlook is positive given deep valuation discounts (P/E 17.9, P/S 0.2) and robust cash flow, but risks include revenue pressure and regulatory scrutiny. Analyst price targets average $35.86, implying significant upside from current levels if execution improves.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
